Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 2/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.54 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.48 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15323203 | 1.00 | LTB4R (0.56) | LTB4RLTB4R2PTGER3PTGDRALDH1A1 | |
| SCHEMBL16589547 | 0.90 | HDAC8 (0.48) | LTB4RLTB4R2PTGER3PTGDRALDH1A1 | |
| SCHEMBL6938553 | 0.80 | LTB4R (0.54) | LTB4RLTB4R2MEN1KMT2ASRD5A2 | |
| SCHEMBL6938556 | 0.80 | LTB4R (0.54) | LTB4RLTB4R2MEN1KMT2ASRD5A2 | |
| SCHEMBL2433126 | 0.80 | LTB4R (0.55) | LTB4RLTB4R2ALDH1A1MEN1KMT2A | |
| SCHEMBL2434205 | 0.79 | NR4A2 (0.58) | LTB4RLTB4R2SRD5A2NPC1RAB9A | |
| SCHEMBL9023060 | 0.79 | LTB4R (0.87) | LTB4RLTB4R2 | |
| SCHEMBL9023059 | 0.79 | LTB4R (0.87) | LTB4RLTB4R2 | |
| SCHEMBL27732143 | 0.78 | CNR1 (0.49) | LTB4RLTB4R2ALDH1A1MEN1KMT2A | |
| SCHEMBL4839242 | 0.77 | ALDH1A1 (0.61) | LTB4RLTB4R2PTGER3PTGDRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499484-B2 | Indole, indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-22 | — | — | US | disclosed |
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-03-26 | — | — | US | disclosed |
| EP-2847165-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013150529-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | IDO1, INMT, IDO2 | LTB4R 862/4885LTB4R2 648/4885PTGER3 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.